"Continuing to Expand Overseas Sales Channels...
Aiming to Increase Global Market Share"

On December 1, Medytox, a biopharmaceutical company, announced that it has obtained product approval for two types of its hyaluronic acid filler "Neuramis" from the National Agency for Medicines and Medical Devices of Albania (AKBPM).

Medytox Obtains Albanian Product Approval for Two Types of Hyaluronic Acid Filler "Neuramis" View original image

Albania is a major emerging country in Eastern Europe. As national income and the proportion of urban population increase, the skin aesthetics and anti-aging markets are steadily growing. Medytox plans to further strengthen its expansion in Europe by successfully launching "Neuramis Deep Lidocaine" and "Neuramis Volume Lidocaine" in Albania, a market with high potential.


"Neuramis" is a hyaluronic acid filler independently developed by Medytox and has proven its product quality through CE certification from the European Union. The company has been accelerating its entry into Europe, having obtained product approval in Serbia in February this year.


A Medytox representative said, "We will accelerate our entry into the Albanian market by leveraging marketing expertise accumulated in Europe," adding, "We will continue to develop overseas sales channels to further increase our global market share."



Meanwhile, since its launch, "Neuramis" has demonstrated its efficacy and safety through over a decade of clinical data. By improving the efficiency of the hyaluronic acid cross-linking reaction, the product's longevity has been enhanced, and by minimizing the residual amount of cross-linker (BDDE), the risk of side effects such as swelling and inflammation has also been reduced. Currently, Medytox has established its presence in the global market by entering 35 countries across Europe, the Middle East, South America, and Asia.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing